Outcomes by prior lines of therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B cell lymphoma.

被引：13
|
作者：
Locke, Frederick Lundry
Ghobadi, Armin
Lekakis, Lazaros J.
Miklos, David Bernard
Jacobson, Caron A.
Jacobsen, Eric D.
Braunschweig, Ira
Oluwole, Olalekan O.
Siddiqi, Tanya
Lin, Yi
Reagan, Patrick Michael
Farooq, Umar
Deol, Abhinav
Bot, Adrian
Rossi, John M.
Jiang, Yizhou
Xue, Allen
Go, William Y.
Neelapu, Sattva Swarup
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[2] Washington Univ, Sch Med, St Louis, MO USA
[3] Univ Miami Hlth Syst, Sylvester Comprehens Care Ctr, Miami, FL USA
[4] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA
[7] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[8] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA
[9] Mayo Clin, Rochester, MN USA
[10] Univ Rochester, Med Ctr, Rochester, NY 14642 USA
[11] Univ Iowa, Iowa City, IA USA
[12] Wayne State Univ, Karmanos Canc Ctr, Detroit, MI USA
[13] Kite, Santa Monica, CA USA
[14] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.3039
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3039
引用
收藏
页数：2
相关论文
共 50 条
  • [11] A Comparison of 2-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel [Axi-Cel]) and SCHOLAR-1 in Patients (Pts) with Refractory Large B Cell Lymphoma (LBCL)
    Neelapu, Sattva S.
    Locke, Frederick L.
    Bartlett, Nancy L.
    Lekakis, Lazaros J.
    Reagan, Patrick M.
    Miklos, David B.
    Jacobson, Caron A.
    Braunschweig, Ira
    Oluwole, Olalekan O.
    Siddiqi, Tanya
    Lin, Yi
    Crump, Michael
    Kuruvilla, John
    Van Den Neste, Eric
    Farooq, Umar
    Navale, Lynn
    DePuy, Venita
    Kim, Jenny J.
    Gisselbrecht, Christian
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S232 - S232
  • [12] A Comparison of 2-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel; Axi-Cel) and SCHOLAR-1 in Patients (Pts) with Refractory Large B Cell Lymphoma (LBCL)
    Neelapu, Sattva S.
    Locke, Frederick L.
    Bartlett, Nancy L.
    Lekakis, Lazaros J.
    Reagan, Patrick
    Miklos, David B.
    Jacobson, Caron A.
    Braunschweig, Ira
    Oluwole, Olalekan
    Siddiqi, Tanya
    Lin, Yi
    Crump, Michael
    Kuruvilla, John
    Van den Neste, Erin
    Farooq, Umar
    Navale, Lynn
    DePuy, Venita
    Kim, Jenny
    Gisselbrecht, Christian
    MOLECULAR THERAPY, 2020, 28 (04) : 575 - 576
  • [13] Axicabtagene Ciloleucel (Axi-Cel) In Patients With Refractory Large B Cell Lymphoma: Long-Term Safety and Efficacy of ZUMA-1
    Neelapu, S. S.
    Ghobadi, A.
    Jacobson, C. A.
    Miklos, D. B.
    Lekakis, L. J.
    Oluwole, O. O.
    Lin, Y.
    Braunschweig, I.
    Hill, B. T.
    Timmerman, J. M.
    Deol, A.
    Reagan, P. M.
    Stiff, P.
    Flinn, I. W.
    Farooq, U.
    Goy, A.
    McSweeney, P. A.
    Munoz, J.
    Siddiqi, T.
    Chavez, J. C.
    Herrera, A. F.
    Xue, A.
    Jiang, Y.
    Bot, A.
    Rossi, J. M.
    Kim, J. J.
    Go, W. Y.
    Locke, F. L.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 26 - 27
  • [14] Retreatment (reTx) of patients (pts) with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1.
    Locke, Frederick Lundry
    Bartlett, Nancy L.
    Jacobson, Caron A.
    Oluwole, Olalekan O.
    Munoz, Javier
    Lekakis, Lazaros J.
    Topp, Max S.
    Avivi, Irit
    Kim, Jenny J.
    Chu, Rong
    Zheng, Lianqing
    Rossi, John M.
    Bot, Adrian
    Neelapu, Sattva Swarup
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [15] Axicabtagene Ciloleucel (Axi-cel) in Patients With Refractory Large B Cell Lymphoma (NHL): Long-term Follow-up of ZUMA-1
    Locke, F. L.
    Bartlett, N. L.
    Lekakis, L. J.
    Miklos, D. B.
    Jacobson, C. A.
    Braunschweig, I.
    Oluwole, O. O.
    Siddiqi, T.
    Lin, Y.
    Timmerman, J.
    Reagan, P. M.
    Bot, A.
    Rossi, J. M.
    Navale, L.
    Jiang, Y.
    Aycock, J. S.
    Elias, M.
    Wiezorek, J. S.
    Go, W.
    Neelapu, S. S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 25 - 25
  • [16] Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma
    Neelapu, Sattva S.
    Jacobson, Caron A.
    Oluwole, Olalekan O.
    Munoz, Javier
    Deol, Abhinav
    Miklos, David B.
    Bartlett, Nancy L.
    Braunschweig, Ira
    Jiang, Yizhou
    Kim, Jenny J.
    Zheng, Lianqing
    Rossi, John M.
    Locke, Frederick L.
    BLOOD, 2020, 135 (23) : 2106 - 2109
  • [17] Characteristics of the pretreatment tumor microenvironment may influence clinical response in patients with refractory large B cell lymphoma treated with axicabtagene ciloleucel (axi-cel) in the pivotal ZUMA-1
    Rossi, John M.
    Galon, Jerome
    Turcan, Sarah
    Danan, Corinne
    Locke, Frederick L.
    Neelapu, Sattva S.
    Miklos, David B.
    Jacobson, Caron A.
    Lekakis, Lazaros J.
    Lin, Yi
    Ghobadi, Armin
    Go, William Y.
    Bot, Adrian
    CANCER RESEARCH, 2018, 78 (13)
  • [18] Long-term (5 year) overall survival in zuma-1, the pivotal study of axicabtagene ciloleucel (axi-cel) in patients with refractory large b-cell lymphoma (LBCL)
    Jacobson, C. A.
    Locke, F. L.
    Ghobadi, A.
    Miklos, D. B.
    Lekakis, L. J.
    Oluwole, O. O.
    Lin, Y.
    Hill, B. T.
    Timmerman, J. M.
    Deol, A.
    Reagan, P. M.
    Stiff, P.
    Flinn, I. W.
    Farooq, U.
    Goy, A. H.
    Munoz, J.
    Siddiqi, T.
    Shen, R. R.
    Bot, A. A.
    Dong, J.
    Singh, K.
    Spooner, C.
    Karalliyadda, R.
    Kim, J. J.
    Zheng, Y.
    Neelapu, S. S.
    BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 131 - 132
  • [19] Clinical Response in ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma, May Be Influenced by Characteristics of the Pretreatment Tumor Microenvironment (TME)
    Rossi, John M.
    Galon, Jerome
    Turcan, Sarah
    Danan, Corinne
    Locke, Frederick L.
    Neelapu, Sattva S.
    Miklos, David B.
    Jacobson, Caron A.
    Lekakis, Lazaros J.
    Lin, Yi
    Ghobadi, Armin
    Go, William Y.
    Bot, Adrian
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S281 - S281
  • [20] Pretreatment immunoscore and an inflamed tumor microenvironment (TME) are associated with efficacy in patients (Pts) with refractory large B cell lymphoma treated with axicabtagene ciloleucel (Axi-Cel) in ZUMA-1
    Rossi, John M.
    Galon, Jerome
    Chang, Edmund
    Perbost, Regis
    Scholler, Nathalie
    Turcan, Sarah
    Danan, Corinne
    Locke, Frederick L.
    Neelapu, Sattva S.
    Miklos, David B.
    Jacobson, Caron A.
    Lekakis, Lazaros J.
    Lin, Yi
    Ghobadi, Armin
    Milletti, Francesca
    Go, William Y.
    Bot, Adrian
    CANCER RESEARCH, 2019, 79 (13)
12345